Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about ADMA, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Asceniv™ | Primary Immune Deficiency | Phase 4 · NCT05070455 | Unknown |
| Bivigam | Humoral Immune Response | Phase 4 · NCT03164967 | Completed |
| Nabi-IGIV 10% [Immune Globulin Intravenous… | Primary Immune Deficiency Disorders (PIDD) | Phase 3 · NCT00538915 | Completed |
| Therapeutic Immune Globulin | Primary Immune Deficiency Disorder | Phase 3 · NCT01814800 | Completed |
| Therapeutic Hepatitis C Immune Globulin | Sequelae of Viral Hepatitis | Phase 2 · NCT00473824 | Terminated |
| High-titer RSV Immune Globulin RI-001 | Upper Respiratory Tract Infection | Phase 2 · NCT00632463 | Completed |
| Other | Primary Immune Deficiency Disorder | N/A · NCT03037359 | Unknown |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
ADMA holds $124.6M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ADMA files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| STATE STREET CORPORATION | Institution (13G, 5%+) | 13,675,348 | 6.16% | 2026-09-30 |
| Rubric Capital Management LP | Institution (13G, 5%+) | 12,352,584 | 5.57% | 2026-09-30 |
| Vanguard Capital Management | Institution (13G, 5%+) | 12,110,153 | 5.46% | 2026-03-31 |
| Adam S Grossman President and CEO, Director · +1.71M options |
Insider | 2,645,734 | 1.19% | 2026-11-16 |
| Steve Elms Director · +17,730 options |
Insider | 2,143,750 | 0.97% | 2026-03-05 |
| Jerrold B Grossman Director · +17,730 options |
Insider | 520,459 | 0.23% | 2026-05-27 |
| Kaitlin M. Kestenberg-Messina COO and SVP, Compliance · +155,801 options |
Insider | 443,061 | 0.20% | 2026-07-24 |
| Young Kwon Director · +17,730 options |
Insider | 263,020 | 0.12% | 2026-02-09 |
| Brad L. Tade CFO and Treasurer |
Insider | 232,940 | 0.10% | 2026-02-19 |
| Terry Kohler CFO and Treasurer · +136,363 options |
Insider | 143,149 | 0.06% | 2026-07-16 |
| Lawrence P. Guiheen Director · +41,567 options |
Insider | 114,589 | 0.05% | 2026-11-16 |
| Alison Cecily Finger Director · +17,730 options |
Insider | 45,619 | 0.02% | 2026-02-09 |
Share count 221,854,389 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ADMA and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →